Dive Brief: The Food and Drug Administration has placed three combination trials of Merck’s flagship immunotherapy Keytruda (pembrolizumab) on clinical hold after a review of the studies found more deaths had occurred in the treatment arms. Merck had previously paused enrollment in two of the trials after initial reports of patient deaths. The three studies now on...